Suspension of trading

News Acorda Therapeutics OTC Markets

Stocks

ACOR

US00484M7002

Biotechnology & Medical Research

Market Closed - OTC Markets 13:47:02 2024-08-21 EDT			5-day change	1st Jan Change
0.0135 ^USD	-3.57%		-10.00%	-99.91%

24-08-13	First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.	CI
24-08-07	Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc.	CI

All News

Mentions Relevance

25-08-06	Federal Circuit Denies Appellate Jurisdiction Based On Alternative Ground For Relief	AQ
24-08-13	First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.	CI
24-08-09	Acorda Therapeutics : UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK Form 8 K	PU
24-08-07	Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc.	CI
24-07-30	First Motion for Exclusivity Period Extension Filed by Acorda Therapeutics, Inc.	CI
24-07-11	Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics	AQ
24-07-09	Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.	CI
24-07-03	Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.	CI
24-07-01	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	CI
24-06-12	Motion for Asset Sale Approved for Acorda Therapeutics, Inc.	CI
24-05-14	Acorda: Q1 Earnings Snapshot	AQ
24-05-14	Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-05-10	Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	CI
24-05-03	Final DIP Financing Approved for Acorda Therapeutics, Inc.	CI
24-04-29	Bidding Procedure Approved for Acorda Therapeutics, Inc.	CI
24-04-15	Acorda Therapeutics Announces Delisting from Nasdaq	BU
24-04-05	Interim DIP Financing Approved for Acorda Therapeutics, Inc.	CI
24-04-04	Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from S&P TMI Index	CI
24-03-31	Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.	CI
23-08-08	Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023